Company

Vanqua Bio

Vanqua Bio develops treatments for neurodegenerative diseases using human genetics and patient-derived neuronal cells.

About

Founded in 2019 and based in Illinois, US, Vanqua Bio develops treatments for neurodegenerative diseases. Its platform uses human genetics and patient-derived neuronal cells to identify and translate disease pathways associated with lysosomal dysfunction. Programs target GCase for Parkinson’s disease and Gaucher disease, as well as immune system activity in ALS and Alzheimer’s disease. The company raised USD 45 million in Series B funding in August 2024.

1Funding rounds

8Investors

Sign in to see more

Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.

Sign in